CompletedPhase 2NCT01658943
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Studying Acinar cell carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Vincent Chung, MDSWOG Cancer Research Network
- Intervention
- Akt Inhibitor MK2206(drug)
- Enrollment
- 137 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2015
Study locations (30)
- The University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
- The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
- Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Mills - Peninsula Hospitals, Burlingame, California, United States
- East Bay Radiation Oncology Center, Castro Valley, California, United States
- Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Epic Care-Dublin, Dublin, California, United States
- Bay Area Breast Surgeons Inc, Emeryville, California, United States
- Epic Care Partners in Cancer Care, Emeryville, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01658943 on ClinicalTrials.govOther trials for Acinar cell carcinoma of pancreas
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerAlliance for Clinical Trials in Oncology
- RECRUITINGPHASE2NCT04858334APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT04657068A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsArtios Pharma Ltd
- RECRUITINGPHASE1NCT04150042SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsGeneral Oncology, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT02834013Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT02757859High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by SurgerySidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE1NCT00669734Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE1NCT00878163GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)